Overview

INPPL1 is altered in 3.41% of all cancers with endometrial endometrioid adenocarcinoma, breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, and invasive breast carcinoma having the greatest prevalence of alterations [3].

The most common alterations in INPPL1 are INPPL1 Mutation (1.72%), INPPL1 Amplification (0.70%), INPPL1 Loss (0.17%), INPPL1 R70H (0.04%), and INPPL1 R691Q (0.02%) [3].

Significance of INPPL1 in Diseases

References

1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.